EGFR and non-small cell lung carcinoma: In reviewing the literature, NSCLC patients receiving EGFR-TKI therapy experienced longer PFS than those treated with chemotherapy,[7,27] and one interesting finding in these 2 articles was that EGFR-TKIs demonstrated greater benefit with the Ex19del and/or L858R mutation than chemotherapy.